<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040854</url>
  </required_header>
  <id_info>
    <org_study_id>CHTV07/2021.1</org_study_id>
    <nct_id>NCT05040854</nct_id>
  </id_info>
  <brief_title>Can we Rely on HLA to Predict Resistance to Biological Therapy in IBD Patients</brief_title>
  <official_title>Can we Rely on HLA to Predict Resistance to Biological Therapy in IBD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar Tondela-Viseu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Hospitalar Tondela-Viseu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose an observational study including patients with inflammatory bowel&#xD;
      disease under biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23&#xD;
      (Ustekinumab), followed by an external Gastroenterology consultation at Centro Hospitalar&#xD;
      Tondela-Viseu.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response to biological therapy</measure>
    <time_frame>36 months</time_frame>
    <description>To assess whether the presence of the HLA-DQA1*05 and HLA DRB1 alleles in patients with inflammatory bowel disease is associated with primary failure or loss of response to biological therapy with anti-TNF (Infliximab and Adalimumab), anti-integrin α₄β₇ (Vedolizumab) or anti-interleukin 12-23 (Ustekinumab).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of HLA-DQ1*05 and DRB1</measure>
    <time_frame>36 months</time_frame>
    <description>To determine the prevalence of HLA-DQ1*05 and DRB1 alleles in IBD population and to compare with a population of healthy blood donor patients.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <description>Blood donors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBD patients - under biological therapy</arm_group_label>
    <description>Patients with IBD followed up in consultation on biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBD patients - naive</arm_group_label>
    <description>Patients newly diagnosed with IBD and need for biological therapy with anti-TNF, anti-integrin α₄β₇ or anti-interleukin 12-23,</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>HLA-DQA1*05 and DRB1</intervention_name>
    <description>All patients will be asked to give blood samples to search for HLA-DQA1*05 and DRB1</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>IBD patients - naive</arm_group_label>
    <arm_group_label>IBD patients - under biological therapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples regarding inflammatory biomarkers and MHC class II&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Inflammatory Bowel Disease under biological therapy with anti-TNF,&#xD;
        anti-integrin α₄β₇ or and anti-interleukin 12-23, followed in a gastroenterology outpatient&#xD;
        consultation at the Centro Hospitalar Tondela-Viseu.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with the diagnosis of IBD (according to ECCO diagnosis criteria);&#xD;
&#xD;
          -  Adult patients (over 18 years);&#xD;
&#xD;
          -  Full capability of signing informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to participate in the study;&#xD;
&#xD;
          -  Patients submitted to prior biological therapy (only for the IBD-naive group)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Ministro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centro Hospitalar Tondela-Viseu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Catarina Carvalho, MD</last_name>
    <phone>+351 232420500</phone>
    <email>8031@hstviseu.min-saude.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paula Ministro, MD</last_name>
    <phone>+351 2324200500</phone>
    <email>paulaministro@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Hospitalar Tondela Viseu</name>
      <address>
        <city>Viseu</city>
        <zip>3504-509</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Ministro, MD</last_name>
      <phone>+351 232420500</phone>
      <email>paulaministro@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Hospitalar Tondela-Viseu</investigator_affiliation>
    <investigator_full_name>Ana Carvalho</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>HLA</keyword>
  <keyword>Biological therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

